Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis
Status:
Completed
Trial end date:
2018-10-19
Target enrollment:
Participant gender:
Summary
The purpose of this study was to collect long-term safety and tolerability, long-term
efficacy, and health outcome data in all patients currently ongoing in the fingolimod
multiple sclerosis clinical development program. This study combined all currently ongoing
Phase II and III fingolimod extension studies as well as ongoing and newly planned studies
into one single long-term extension protocol that provided patients with continuous treatment
until fingolimod was registered, commercially available, and reimbursed in the respective
countries.